Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK006 in breast cancer-related bone metastases
NCT03239756Phase 1Unknown
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- Jul 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TK006 in bone metastasis (4 arms), sponsored by Jiangsu T-mab Biopharma Co., Ltd. Primary endpoint: Adverse Events at 140 days. Status: unknown.
02
Drugs
TK006
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT03239756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239756.